Nooshin Dalili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nooshin Dalili has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Fariba Samadian
Shahid Beheshti Univ Med Sci, Chron Kidney Dis Res Ctr, Shahid Labbafinejad Med Ctr, Boustan 9,Pasdaran Ave, Tehran, Iran
9 shared publications- Mohsen Nafar
Shahid Beheshti University of Medical Sciences
7 shared publications Pedram Ahmadpoor
Chronic Kidney Disease Research Center (CKDRC), Shahid Beheshti University of Medical Sciences, Iran; Department of Nephrology, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 shared publications- Shiva Samavat
Chronic Kidney Disease Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 shared publications Mohsen Nafar
Chronic Kidney Disease Research Center (CKDRC), Department of Nephrology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Division of Nephrology, Department of Internal Medicine, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 shared publicationsShiva Samavat
Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Determinants of the renal function after the coronary artery bypass grafting in chronic kidney disease patients: a prospective cohort study
Background: This study aims to evaluate renal outcomes and identify key factors influencing estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease(CKD) undergoing coronary artery bypass grafting (CABG). Methods: In a prospective cohort of 100 patients with CKD (mean age 65.5 years; 77% male; most in CKD stage 2 or 3), eGFR was measured at baseline, three months, and six months postoperatively. Generalized Estimating Equations (GEE) were applied to assess longitudinal changes in eGFR and associated predictors. Statistical analyses were performed using Stata 17. Results: Approximately 19% of patients experienced a > 30% decline in eGFR, while over 40% demonstrated improvement at six months. Advanced CKD stage, higher preoperative heart ejection fraction (EF), and longer anesthesia time were associated with greater eGFR decline. Conversely, higher preoperative hemoglobin (Hb) levels, elective surgery, and a history of cerebrovascular accident were associated with improved estimated eGFR trends. Conclusion: Several clinical and procedural factors influence postoperative renal function in CKD patients undergoing CABG. These findings support the development of targeted perioperative strategies to mitigate renal decline. Clinical trial registration: This study does not meet the criteria of a clinical trial and, therefore, was not registered in a clinical trial registry.
- 15 April 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1)
Open AccessDeterminants of the renal function after the coronary artery bypass grafting in chronic kidney disease patients: a prospective cohort study
Background: This study aims to evaluate renal outcomes and identify key factors influencing estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease(CKD) undergoing coronary artery bypass grafting (CABG). Methods: In a prospective cohort of 100 patients with CKD (mean age 65.5 years; 77% male; most in CKD stage 2 or 3), eGFR was measured at baseline, three months, and six months postoperatively. Generalized Estimating Equations (GEE) were applied to assess longitudinal changes in eGFR and associated predictors. Statistical analyses were performed using Stata 17. Results: Approximately 19% of patients experienced a > 30% decline in eGFR, while over 40% demonstrated improvement at six months. Advanced CKD stage, higher preoperative heart ejection fraction (EF), and longer anesthesia time were associated with greater eGFR decline. Conversely, higher preoperative hemoglobin (Hb) levels, elective surgery, and a history of cerebrovascular accident were associated with improved estimated eGFR trends. Conclusion: Several clinical and procedural factors influence postoperative renal function in CKD patients undergoing CABG. These findings support the development of targeted perioperative strategies to mitigate renal decline. Clinical trial registration: This study does not meet the criteria of a clinical trial and, therefore, was not registered in a clinical trial registry.
- Open Access
- 1 June 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (1)
Evaluating the Predictive Value of a Cardiac Perfusion Scan for Cardiac Events in Chronic Kidney Disease
Background: Cardiovascular diseases are among the leading causes of morbidity and mortality in chronic kidney disease (CKD) patients. Therefore, predicting cardiac events in CKD patients is essential. Objectives: The present study aims to evaluate the predictive value of single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients with different stages of CKD. Methods: Consecutive CKD patients with an estimated glomerular filtration rate (eGFR
- 1 June 2024
- Published by Brieflands in International Journal of Cardiovascular Practice
- Vol. 9 (1)
Open AccessEvaluating the Predictive Value of a Cardiac Perfusion Scan for Cardiac Events in Chronic Kidney Disease
Background: Cardiovascular diseases are among the leading causes of morbidity and mortality in chronic kidney disease (CKD) patients. Therefore, predicting cardiac events in CKD patients is essential. Objectives: The present study aims to evaluate the predictive value of single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in patients with different stages of CKD. Methods: Consecutive CKD patients with an estimated glomerular filtration rate (eGFR
- 19 September 2022
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (3) , 697-709
The relationship between CT value and clinical outcomes in renal patients with COVID-19
Purpose Concomitant kidney diseases raise the mortality rate due to the SARS-CoV-2 virus as an independent factor. Although a qualitative PCR test’s result is sufficient for diagnosis, Cycle threshold value may present relevant information to the physicians in providing faster treatment in patients with chronic conditions, including kidney diseases, to prevent morbidity and subsequent mortality. Thus, the present study was conducted to determine the relationship between the Cycle threshold value and clinical outcomes in renal patients with the coronavirus 2019. Methods This retrospective study was conducted on renal patients with the coronavirus 2019 infection admitted to Labbafinejad Hospital in Tehran, the capital of Iran, within a period of one year, from late February 2020 to February 2021. Data were collected per the prepared checklist. Cycle threshold values were measured by performing PCR on nasopharynx and oropharynx swab samples of patients. Results According to the adjusted analysis, having high viral load increased the odds of in-hospital mortality (aOR = 11.65, 95% CI 3.93–34.54), ICU admission (aOR = 5.49, 95% CI 2.16–13.97), and invasive ventilation (aOR = 7.18, 95% CI 2.61–19.74). Having high viral load also increased the odds of O2 therapy (aOR = 3.08, 95% CI 0.79–12.01), although the difference was not statistically significant (P = 0.105). Conclusion Cycle threshold value was a significant predictor of mortality in renal patients. Nevertheless, further studies are required on how to render optimal use of the Cycle threshold value, given that the quality of the test sample and the different groups of patients under study affect the effectiveness of this marker in predicting disease severity.
- 19 September 2022
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (3) , 697-709
The relationship between CT value and clinical outcomes in renal patients with COVID-19
Purpose Concomitant kidney diseases raise the mortality rate due to the SARS-CoV-2 virus as an independent factor. Although a qualitative PCR test’s result is sufficient for diagnosis, Cycle threshold value may present relevant information to the physicians in providing faster treatment in patients with chronic conditions, including kidney diseases, to prevent morbidity and subsequent mortality. Thus, the present study was conducted to determine the relationship between the Cycle threshold value and clinical outcomes in renal patients with the coronavirus 2019. Methods This retrospective study was conducted on renal patients with the coronavirus 2019 infection admitted to Labbafinejad Hospital in Tehran, the capital of Iran, within a period of one year, from late February 2020 to February 2021. Data were collected per the prepared checklist. Cycle threshold values were measured by performing PCR on nasopharynx and oropharynx swab samples of patients. Results According to the adjusted analysis, having high viral load increased the odds of in-hospital mortality (aOR = 11.65, 95% CI 3.93–34.54), ICU admission (aOR = 5.49, 95% CI 2.16–13.97), and invasive ventilation (aOR = 7.18, 95% CI 2.61–19.74). Having high viral load also increased the odds of O2 therapy (aOR = 3.08, 95% CI 0.79–12.01), although the difference was not statistically significant (P = 0.105). Conclusion Cycle threshold value was a significant predictor of mortality in renal patients. Nevertheless, further studies are required on how to render optimal use of the Cycle threshold value, given that the quality of the test sample and the different groups of patients under study affect the effectiveness of this marker in predicting disease severity.
- 21 January 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13798
Humoral immunity of BBIBP‐CorV (Sinopharm) in kidney transplant recipients: Is it time to revise vaccination strategies
Background: The mortality of coronavirus disease 2019 (COVID‐19) is high in transplant patients, and effective vaccination is aimed to reduce severe disease and mortality.Methods: We conducted a cross‐sectional study to evaluate humoral and cellular response to two 4‐μg doses of BBIBP‐CorV vaccine in 100 kidney transplant recipients, using anti‐spike IgG, total anti‐receptor‐binding domain, neutralizing antibody (Ab) level (enzyme‐linked immunoassay), and interferon‐gamma release assay (IGRA).Results: Seroconversion was evaluated 85.84 ± 30.72 days after the second dose. Note that, 58% of all and 43.05% of infection‐naïve participants have developed at least one of the tested antibodies. IGRA was positive in 30.7% of tested transplant recipients. Sixty percent of the participants had either humoral or cellular responses to COVID‐19. Only age was independently linked to seropositivity of any degree after vaccination (p < .05). COVID‐naïve patients older than 60 years developed significantly less neutralizing Abs. (p = .011). Six patients developed mild COVID infection more than a month after the second dose of the vaccine (54.5 ± 20.8 days). No vaccine‐related adverse effects were reported, except self‐limited mild to moderate fever and injection site pain.Conclusion: BBIBP‐CorV vaccine can be used safely in kidney transplant recipients, although impaired cellular and humoral immunity necessitate adjustments in vaccination strategies, like higher (8‐μg doses), fourth booster dose, or boost with different platform vaccine.
- 21 January 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13798
Humoral immunity of BBIBP‐CorV (Sinopharm) in kidney transplant recipients: Is it time to revise vaccination strategies
Background: The mortality of coronavirus disease 2019 (COVID‐19) is high in transplant patients, and effective vaccination is aimed to reduce severe disease and mortality.Methods: We conducted a cross‐sectional study to evaluate humoral and cellular response to two 4‐μg doses of BBIBP‐CorV vaccine in 100 kidney transplant recipients, using anti‐spike IgG, total anti‐receptor‐binding domain, neutralizing antibody (Ab) level (enzyme‐linked immunoassay), and interferon‐gamma release assay (IGRA).Results: Seroconversion was evaluated 85.84 ± 30.72 days after the second dose. Note that, 58% of all and 43.05% of infection‐naïve participants have developed at least one of the tested antibodies. IGRA was positive in 30.7% of tested transplant recipients. Sixty percent of the participants had either humoral or cellular responses to COVID‐19. Only age was independently linked to seropositivity of any degree after vaccination (p < .05). COVID‐naïve patients older than 60 years developed significantly less neutralizing Abs. (p = .011). Six patients developed mild COVID infection more than a month after the second dose of the vaccine (54.5 ± 20.8 days). No vaccine‐related adverse effects were reported, except self‐limited mild to moderate fever and injection site pain.Conclusion: BBIBP‐CorV vaccine can be used safely in kidney transplant recipients, although impaired cellular and humoral immunity necessitate adjustments in vaccination strategies, like higher (8‐μg doses), fourth booster dose, or boost with different platform vaccine.
- 1 November 2021
- Published by Maad Rayan Publishing Company
- Vol. 15 (6) , 441-450
Prognostic Value of Blood Pressure Responsiveness in Hemodialysis for Cardiovascular Mortality, Development of A New Predictive Equation
Introduction. Cardiovascular disease is considered as the main cause of mortality and morbidity in HD-patients and AS is a fundamental cause. This study was conducted to investigate whether intradialytic BP changes can use as a surrogate clinical marker. Methods. Fifty-one patients on maintenance hemodialysis, for at least 12 hours per week, were included in a prospective cohort study. Intradialytic BP was measured using validated automated device. PWV was performed to assess Augmentation Index (AIx) as marker of arterial stiffness. All measurements were repeated in alive individuals after 5 years of follow-up. Patients with 5% reduction of intradialytic BP were considered as HD-responsive and Several statistical analyses were employed based on responsiveness to HD. Results. After 5-year follow-up the findings demonstrated BP response to HD was an important and independent determinant of mortality (P < .05). Augmentation index (AIx) (P < .05), heart rate (P < .05), and calcium phosphate product (P < .05) as well as log PTH (P < .05) were significantly different between two responsive and non-responsive to HD. Pearson's Correlation studies revealed a significant relationship between the BP response to HD and heart rate (r = 0.4, P < .05), LVEF (r =-0.4, P < .05) and PTH (r =-0.3, P < .05). BP response to HD and log-PTH remained significant even after age and gender adjustment (P < .05). Conclusion. BP-response to HD can use as a clinical and surrogate marker of AS which is significantly associated with mortality and LVEF. Arterial stiffness and intradialytic BP can predict the changes in Ejection Fraction (EF).
- 1 November 2021
- Published by Maad Rayan Publishing Company
- Vol. 15 (6) , 441-450
Prognostic Value of Blood Pressure Responsiveness in Hemodialysis for Cardiovascular Mortality, Development of A New Predictive Equation
Introduction. Cardiovascular disease is considered as the main cause of mortality and morbidity in HD-patients and AS is a fundamental cause. This study was conducted to investigate whether intradialytic BP changes can use as a surrogate clinical marker. Methods. Fifty-one patients on maintenance hemodialysis, for at least 12 hours per week, were included in a prospective cohort study. Intradialytic BP was measured using validated automated device. PWV was performed to assess Augmentation Index (AIx) as marker of arterial stiffness. All measurements were repeated in alive individuals after 5 years of follow-up. Patients with 5% reduction of intradialytic BP were considered as HD-responsive and Several statistical analyses were employed based on responsiveness to HD. Results. After 5-year follow-up the findings demonstrated BP response to HD was an important and independent determinant of mortality (P < .05). Augmentation index (AIx) (P < .05), heart rate (P < .05), and calcium phosphate product (P < .05) as well as log PTH (P < .05) were significantly different between two responsive and non-responsive to HD. Pearson's Correlation studies revealed a significant relationship between the BP response to HD and heart rate (r = 0.4, P < .05), LVEF (r =-0.4, P < .05) and PTH (r =-0.3, P < .05). BP response to HD and log-PTH remained significant even after age and gender adjustment (P < .05). Conclusion. BP-response to HD can use as a clinical and surrogate marker of AS which is significantly associated with mortality and LVEF. Arterial stiffness and intradialytic BP can predict the changes in Ejection Fraction (EF).
- 9 July 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (11)
Early post‐operative acute kidney injury after cardiac transplantation: Incidence and predictive factors
Background: Heart transplantation, as a therapeutic option for patients with advanced heart failure, possesses a high rate of morbidity and mortality. One of the complications associated with this procedure is the development of postoperative acute kidney injury (AKI)Material and methods: We aimed to evaluate the incidence of early postoperative AKI and the need for continuous renal replacement therapy (RRT) after heart transplantation. Data of 126 patients who underwent heart transplantation from January 2015 to November 2019 were collected. Statistical analysis was performed to identify the predictors of postoperative AKI.Results: Out of 126 patients, 74 (58.7 %) developed AKI and 13 (10%) required RRT after transplant. Independent predictors of AKI are shown to be factors associated with surgical procedures such as graft ischemic time as were previous cardiac operation, administered Voluven (starch) dose > 400 ml, and transfusion of more than four blood units.Conclusion: Our findings suggest that modifiable factors exist that can affect the risk of developing AKI following heart transplantation.
- 9 July 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (11)
Early post‐operative acute kidney injury after cardiac transplantation: Incidence and predictive factors
Background: Heart transplantation, as a therapeutic option for patients with advanced heart failure, possesses a high rate of morbidity and mortality. One of the complications associated with this procedure is the development of postoperative acute kidney injury (AKI)Material and methods: We aimed to evaluate the incidence of early postoperative AKI and the need for continuous renal replacement therapy (RRT) after heart transplantation. Data of 126 patients who underwent heart transplantation from January 2015 to November 2019 were collected. Statistical analysis was performed to identify the predictors of postoperative AKI.Results: Out of 126 patients, 74 (58.7 %) developed AKI and 13 (10%) required RRT after transplant. Independent predictors of AKI are shown to be factors associated with surgical procedures such as graft ischemic time as were previous cardiac operation, administered Voluven (starch) dose > 400 ml, and transfusion of more than four blood units.Conclusion: Our findings suggest that modifiable factors exist that can affect the risk of developing AKI following heart transplantation.
- 11 July 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (5) , e13406
Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?
Background: With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.Methods: We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.Results: Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.Conclusions: Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality.
- 11 July 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 22 (5) , e13406
Low rate of COVID‐19 pneumonia in kidney transplant recipients—A battle between infection and immune response?
Background: With COVID‐19 pandemic, concerns about kidney transplant recipients are rising. However, the incidence, clinical course, outcome, and predictive factors of disease severity are obscured.Methods: We describe clinical and laboratory manifestations, radiologic findings, clinical course, and finally outcome of kidney transplant recipients with COVID‐19 pneumonia.Results: Of 2493 kidney transplant recipients under follow‐up in our clinic, 19 cases (4 cases diagnosed based on radiologic findings) were admitted. The mean age of patients was 47.6 ± 12.4 years, and the mean time from transplantation was 115.6 ± 70.3 months. Lymphopenia and eosinopenia were 84.2% and 78.9%, respectively. Nine patients did not survive the hospital course. History of acute rejection during the past 12 months, diabetes, higher N/L ratio, lower platelet count, elevated N/L x CRP, higher levels of LDH, positive D‐dimer, higher troponin, and prolonged PT were associated with mortality. Among patients with positive COVID‐19 test, history of acute rejection, low platelet count, and positive D‐dimer were associated with poor outcome. Treatment with cyclosporine was associated with better clinical outcome.Conclusions: Low rate of admission in transplant recipients specially in the very first years of transplantation might be due to protective effects of immunosuppressive agents against cytokine storm or modification of immunity function. We suggest evaluation of T‐cell number, function, and cytokine profile as a guide to manage COVID‐19 mainly in patients with higher risk of mortality.
- 1 July 2020
- Vol. 14 (4) , 267-277
Clinical and Radiologic Characteristics of COVID-19 in Patients With CKD
Introduction. In this study, we aimed to evaluate the presentation and outcome of COVID-19 in patients with chronic kidney disease (CKD). Methods. We included 43 patients with a past history of CKD and confirmed diagnosis of COVID-19. Patients were evaluated for demographic characteristics, clinical and laboratory data and findings of initial chest computed tomography (CT) and were followed until either death or discharge occurred. Then, study variables were compared based on final outcome and stage of CKD. Results. Mean age +/- SD of patients was 60.65 +/- 14.36 years; 65.1% were male. Five of 43 patients (11.6%) died on follow-up and the rest were discharged. Disease outcome did not differ across CKD stages (P > .05). More than half of the patients (58.1%) presented with severe disease on admission. Clinical symptoms were similar to those of non-CKD individuals. Mean duration of hospitalization was higher in those who died, although not significant (16.6 +/- 8.38 vs. 11 +/- 6.26, P > .05). The only hematologic parameter that significantly differed between survivors and non-survivors was lactase dehydrogenase level (P < .05). Ground-glass opacification and reticular pattern were the most frequent patterns on CT and pleural effusion existed in about one-fifth of all patients. A greater lower zone score was noted in deceased patients (P < .05). Conclusion. Patients with CKD are vulnerable to a more severe form of COVID-19 and experience a higher mortality rate than the general population; however, higher CKD stage is not related to worse prognosis or different imaging manifestation compared with lower stage.
- 1 July 2020
- Vol. 14 (4) , 267-277
Clinical and Radiologic Characteristics of COVID-19 in Patients With CKD
Introduction. In this study, we aimed to evaluate the presentation and outcome of COVID-19 in patients with chronic kidney disease (CKD). Methods. We included 43 patients with a past history of CKD and confirmed diagnosis of COVID-19. Patients were evaluated for demographic characteristics, clinical and laboratory data and findings of initial chest computed tomography (CT) and were followed until either death or discharge occurred. Then, study variables were compared based on final outcome and stage of CKD. Results. Mean age +/- SD of patients was 60.65 +/- 14.36 years; 65.1% were male. Five of 43 patients (11.6%) died on follow-up and the rest were discharged. Disease outcome did not differ across CKD stages (P > .05). More than half of the patients (58.1%) presented with severe disease on admission. Clinical symptoms were similar to those of non-CKD individuals. Mean duration of hospitalization was higher in those who died, although not significant (16.6 +/- 8.38 vs. 11 +/- 6.26, P > .05). The only hematologic parameter that significantly differed between survivors and non-survivors was lactase dehydrogenase level (P < .05). Ground-glass opacification and reticular pattern were the most frequent patterns on CT and pleural effusion existed in about one-fifth of all patients. A greater lower zone score was noted in deceased patients (P < .05). Conclusion. Patients with CKD are vulnerable to a more severe form of COVID-19 and experience a higher mortality rate than the general population; however, higher CKD stage is not related to worse prognosis or different imaging manifestation compared with lower stage.
- Open Access
- 5 June 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-3
Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial
Objectives: Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients. Trial design: Prospective, randomized (1:1 ratio), double blind study with parallel group design. Participants: Hospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation. Exclusion criteria: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)450 msec. Participants will be recruited from inpatients at Labbafinejad Meidcal Center , Tehran, Iran. Intervention and comparator: Eligible enrolled patients will be randomized into two groups. Group A will receive the antiretroviral Lopinavir/Ritonavir (Kaletra) while group B will receive Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally. All patients in both groups will receive the same amounts of essential minerals, vitamins as antioxidants, and antibiotics. Patients of both groups will be treated under optimal treatment based on the CDC and WHO guidelines and national consensus proposed in Iran including the same dosages of Lopinavir/Ritonavir, antibiotics, trace elements and antioxidants while only in group-B patients Colchicine will be added on top of this protocol. Main outcomes: Primary: Time for clinical improvement and lung CT score changes 14 days after treatment. Secondary: 14 days after treatment – C-Reactive Protein test x Neutrophil to Lymphocyte Ratio , Interleukin-6, malondialdehyde (MDA) levels reduction – Percentage of patients who require supplemental Oxygen – Mean hospital stay length Randomisation: Patients will be allocated to each group (ratio 1:1) by using an online randomization tool: http://www.graphpad.com/quickcalcs/index.cfm Blinding (masking): This will be a double-blind study in which participants and those assessing the final outcomes will be blinded to group assignment. Numbers to be randomised (sample size): Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients. Trial Status: Recruitment is ongoing. Recruitment began on 20/03/2020 and the date by which the recruitment is anticipated to be completed is 30/05/2020. Trial registration: ClinicalTrials.gov Identifier: NCT04360980, registered 24/04/2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
- 5 June 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-3
Open AccessAdding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial
Objectives: Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reducing Intereukin-6, Interleukin-8, Tumour Necrosis Factor-alpha besides controlling oxidative stress pathways which all are important and pathologic components in the clinical course and outcome of patients infected with COVID-19. This study aims to assess the anti-inflammatory effects of colchicine in non-severe hospitalized COVID-19 patients. Trial design: Prospective, randomized (1:1 ratio), double blind study with parallel group design. Participants: Hospitalized patients with positive nasopharyngeal swab for COVID-19 infection (RT -PCR) and lung Computed tomography scan involvement compatible with COVID-19 pneumonia. The patients are not severely hypoxic, do not need intubation or invasive oxygenation. Exclusion criteria: known hypersensitivity to colchicine; known hepatic failure; estimated glomerular filtration rate (eGFR)450 msec. Participants will be recruited from inpatients at Labbafinejad Meidcal Center , Tehran, Iran. Intervention and comparator: Eligible enrolled patients will be randomized into two groups. Group A will receive the antiretroviral Lopinavir/Ritonavir (Kaletra) while group B will receive Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally. All patients in both groups will receive the same amounts of essential minerals, vitamins as antioxidants, and antibiotics. Patients of both groups will be treated under optimal treatment based on the CDC and WHO guidelines and national consensus proposed in Iran including the same dosages of Lopinavir/Ritonavir, antibiotics, trace elements and antioxidants while only in group-B patients Colchicine will be added on top of this protocol. Main outcomes: Primary: Time for clinical improvement and lung CT score changes 14 days after treatment. Secondary: 14 days after treatment – C-Reactive Protein test x Neutrophil to Lymphocyte Ratio , Interleukin-6, malondialdehyde (MDA) levels reduction – Percentage of patients who require supplemental Oxygen – Mean hospital stay length Randomisation: Patients will be allocated to each group (ratio 1:1) by using an online randomization tool: http://www.graphpad.com/quickcalcs/index.cfm Blinding (masking): This will be a double-blind study in which participants and those assessing the final outcomes will be blinded to group assignment. Numbers to be randomised (sample size): Regarding the pandemic crisis and our center capacity to hospitalize confirmed COVID-19 patients, a total of 80 patients was found to be logical to be randomized into two groups of 40- patients. Trial Status: Recruitment is ongoing. Recruitment began on 20/03/2020 and the date by which the recruitment is anticipated to be completed is 30/05/2020. Trial registration: ClinicalTrials.gov Identifier: NCT04360980, registered 24/04/2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.